Recorded a special income of 1,882 million yen from a grant by the Ministry of Health, Labour and Welfare in the third quarter of the fiscal year ending March 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharmaceuticals Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-01-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4552-20260128-04.pdf","jir_short_summary":"Recorded a special income of 1,882 million yen from a grant by the Ministry of Health, Labour and Welfare in the third quarter of the fiscal year ending March 2026.","jir_summary":"### Details of Special Income (Grant Income)\nJCR Pharmaceuticals Co., Ltd. recorded special income of 1,882 million yen in the third quarter of the fiscal year ending March 2026, relating to the grant received from the Ministry of Health, Labour and Welfare for the construction of the Kobe Science Park Center (API factory). This amount was determined by deducting the asset retirement amount of fixed assets and unused refundable portions from grants previously received and recorded in a deferred special account.\n\n### Impact on Financial Performance\nFor the impact of this special income on financial results, please refer to the \"Financial Summary for the Third Quarter of the Fiscal Year Ending March 2026 [Japanese GAAP] (Consolidated)\" announced on the same day.","jir_financial_highlights":"Special Income (Grant Income): 1,882 million yen (Unknown)","jir_category":"","jir_hashtags":"#JCRPharmaceuticals, #financial_summary, #special_income","jir_key_figures":"Special Income (Grant Income): 1,882 million yen (Recorded in Q3 of fiscal year ending March 2026)\nGrant Target Facility: Kobe Science Park Center (API Factory)\nAccounting Period: October 1, 2025 - December 31, 2025","jir_meta_title":"JCR Pharmaceuticals Records Special Income of 1,882 Million Yen from Grant in Q3 Fiscal Year Ending March 2026","jir_meta_description":"JCR Pharmaceuticals Co., Ltd. recorded special income of 1,882 million yen from a grant by the Ministry of Health, Labour and Welfare in the third quarter of the fiscal year ending March 2026, related to the construction of Kobe Science Park Center.","jir_og_title":"JCR Pharmaceuticals Records 1,882 Million Yen Special Income from Grant","jir_og_description":"Announced recording of special income of 1,882 million yen from a grant by the Ministry of Health, Labour and Welfare in Q3 of the fiscal year ending March 2026.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-21428","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n